Ready to revolutionize your lab work? Join us as we dive deep into bead-based assays with Sebastian Giehring, CEO and founder of PAIA Biotech.
Discover how these tiny beads are making a massive impact on biotech research and development — for titer, glycan, and aggreation screening — and how this developability screening platform can enhance your antibody discovery, antibody engineering and lead optimization.
In this episode, you’ll learn:
- Speed and Simplicity: How bead-based assays offer unmatched throughput and ease of use, allowing you to analyze hundreds of samples in just a few steps.
- Versatile Applications: The diverse applications of bead-based assays in cell development, bioprocessing, and antibody discovery, helping streamline workflows and enhance innovation.
- Early Screening Advantages: The benefits of bead-based assays in early-stage process development, enabling quick decision-making with less detailed but rapid results.
Tune in to uncover how these assays can transform your biotech research and push the boundaries of what's possible!
Connect with Sebastian Giehring:
LinkedIn: https://www.linkedin.com/in/sebastian-giehring-6ba1992
PAIA Biotech: https://www.paiabio.com
Next Steps:
Book a free assessment to help you get started with the design of your next experiment at https://bruehlmann-consulting.com
Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com
Support the show
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation